Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.

Initial data on Amgen’s AMG 193 give some Tango investors a headache.

The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.

Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.

Tempest Therapeutics confirms an earlier success with its lead project, and this time investors respond.

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.

ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.

With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.